Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
EO14042 - THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. is a federal Unrestricted award for National Institutes Of Health Niaid held by Infectious Disease Research Institute. Estimated value $11.3M ($4.9M obligated). Current period of performance ends Aug 31, 2026. Last award drew 24 bidders. Place of performance: SEATTLE WA. Related solicitation HHSNIHNIAIDBAA20171.
EO14042 - THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS.
Recompete timing
PublicCurrent PoP ended Aug 31, 2026 (27 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 75N93018C00025? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordInfectious Disease Research Institute — $7.9M obligated across 4 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N93018C00025?
75N93018C00025 (Eo14042 - the purpose of THIS) is a National Institutes Of Health Niaid award with a potential value of $11.3M, currently held by Infectious Disease Research Institute. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N93018C00025?
National Institutes Of Health Niaid awarded 75N93018C00025 to Infectious Disease Research Institute (potential $11.3M).
Who is the incumbent on 75N93018C00025?
Infectious Disease Research Institute is the incumbent with $7.9M across 4 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2026.
When does Infectious Disease Research Institute’s 75N93018C00025 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75N93018C00025? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.